Income Statement (Annual)

LJPC / La Jolla Pharmaceutical Co. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2010 2011 2012 2013 2014 2015 2016 2017
Revenues
  Revenue From Contract With Customer Including Assessed Tax - - - - - - - -
  Revenues - - - 0 0 1,057 616 0
Costs And Expenses
  Cost Of Goods And Services Sold - - - - - - - -
  Research And Development Expense 13 177 1,353 4,362 9,944 29,092 62,288 84,575
  General And Administrative Expense 3,915 2,097 9,386 13,577 11,396 13,934 16,700 30,852
  Costs And Expenses 3,928 2,274 10,739 17,939 21,340 43,026 78,988 115,427
Operating Income Loss -3,928 -2,274 -10,739 -17,939 -21,340 -41,969 -78,372 -115,427
Other Nonoperating Income Expense -1 234 4 4 27 57 187 624
Net Income Loss -3,760 -11,548 -7,737 -17,935 -21,313 -41,912 -78,185 -114,803
Earnings Per Share Basic And Diluted -0 -0 -0 -0 -0 -0 -0 -0
Weighted Average Number Of Share Outstanding Basic And Diluted - 369 10,196 454,337 10,667 15,651 17,228 21,215

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related Articles

HIMX: Himax Technologies Analysis and Research Report

15h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

CUSIP: 503459604